Non-myeloablative allogeneic stem cell transplant: Achievements and perspectives

T. Saito, Shin Mineishi

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

In the past concept, conditioning regimens for allogeneic hematopoietic stem cell transplantation (HSCT) were assumed to have two roles: myeloablation and immunosuppression. Recent clinical and experimental data have shown that intense immunosuppression, rather than myeloablation, is the primary requirement for stable engraftment and that the main therapeutic component of allogeneic HSCT is attributed to graft-versus-leukemia/tumor (GVL/T) effect mediated by donor-derived T cells. Based on these findings, a new strategy of non-myeloablative stem cell transplantation (NST) has been developed for patients who are ineligible for conventional stem cell transplantation (CST) because of the old age or organ dysfunction. Recent reports from many transplant centers have shown that application of NST decreased regimen-related toxicities (RRT), while associated with consistent stable engraftment. In this review we overview the clinical development (background, clinical experience), remaining problems and future directions of NST.

Original languageEnglish (US)
Pages (from-to)4-10
Number of pages7
JournalExperimental Oncology
Volume23
Issue number1
StatePublished - Mar 1 2001

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Non-myeloablative allogeneic stem cell transplant: Achievements and perspectives'. Together they form a unique fingerprint.

  • Cite this